SC asks Centre to respond on clinical trial of vaccines

Image
Press Trust of India New Delhi
Last Updated : Jan 13 2015 | 9:30 PM IST
Supreme Court today asked the Centre to file its response giving details like process of taking consent of persons on whom clinical trial of cervical cancer prevention vaccines, Gardasil and Cervarix, have been carried out.
A bench of justices Dipak Misra and Prafulla C Pant asked the Centre to also indicate who would be liable to pay compensation to the persons if the clinical trial of the vaccination caused adverse impact.
Besides the Centre, the bench also asked governments of Gujarat, Andhra Pradesh and Telangana, where clinical trials of the vaccines have taken place, to file their responses within four weeks about issues including the number of affected persons.
The bench asked the Centre to keep in view the 81st report of the Parliamentary Standing Committee on clinical trial of vaccines while filing its response.
During the hearing, the counsel for Gujarat said seven deaths were reported from the state and moreover, these did not happen due to the clinical trials but were rather caused by reasons including snake bites.
The court, however, did not concur with the submission.
Earlier, the court had asked the Centre to place before it the records regarding the licenses given to cervical cancer prevention vaccines, Gardasil and Cervarix.
It had directed the Centre to place before it the report of Parliamentary Standing Committee on Health and Family Welfare which has dealt with the issue of drugs relating to Human Papilloma Virus (HPV) vaccine.
The court had allowed to make Gujarat, Andhra Pradesh and Telangana as respondents in the matter as some villages in these states were chosen for administering the vaccine as an experiment and reports had allegedly suggested that girls suffered side effects of Gardasil and Cervarix, manufactured by pharmaceuticals major Merck Sharpe and Dohme respectively.
The bench said it had to examine whether proper protocol and procedure was followed for introduction of these vaccines because it has been alleged that deaths have also been caused due to the situation.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 13 2015 | 9:30 PM IST

Next Story